Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Félix, Lefort"'
Autor:
Laurence Albiges, Bernard Escudier, Gwenaelle Gravis, Ronan Flippot, Alain Ravaud, Maxime Meylan, Nathalie Rioux-Leclercq, Marine Gross-Goupil, Gaëlle Fromont, Christophe Passot, Lionnel Geoffrois, Fréderic Rolland, Manon de Vries-Brilland, Jonathan Dauvé, Elena Spirina-Menand, Christine Chevreau, Ellen Blanc, Félix Lefort, Sylvie Negrier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC, and associated with poor outcomes in the metastatic setting. In this study, we aimed to comprehensively evaluate the immune tumor microenvironment (TME), largely
Externí odkaz:
https://doaj.org/article/e2ce2468aad14a5187730a92accb65ce
Autor:
Samuel Bitoun, Marie Kostine, Christophe Richez, Thomas Barnetche, Thierry Schaeverbeke, Gael Mouterde, Marie-Elise Truchetet, Maéva Zysman, Amaury Daste, Sorilla Prey, Alice Tison, Rémi Veillon, Caroline Dutriaux, Anne Pham-Ledard, Marie Beylot-Barry, Marine Gross-Goupil, Félix Lefort, Alexandra Ladouceur, Emilie Gerard, Charlotte Domblides, Baptiste Sionneau, Mathieu Larroquette
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Objective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety
Externí odkaz:
https://doaj.org/article/dd729db8de80406ebd7112cf82a7704c
Autor:
Félix Lefort, Raul Perret, Mokrane Yacoub, Jessica Baud, Jean-Christophe Bernhard, François Le Loarer
Publikováno v:
Histopathology. 80:745-748
Thyroid-like follicular renal cell carcinoma (TFRCC) is rare, with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5f5af1ddc294b37b23932f986086054
https://doi.org/10.1111/his.14589
https://doi.org/10.1111/his.14589
Autor:
Félix Lefort, Charlotte Domblides, Baptiste Sionneau, Amandine Quivy, Marine Gross-Goupil, Pauline Bertolaso, Mathieu Larroquette, Alain Ravaud, Amaury Daste, Matthieu Lasserre
Publikováno v:
European Journal of Cancer. 158:47-62
The use of immune checkpoint inhibitors (ICIs), especially anti-programmed cell death 1 (PD1) and anti-programmed cell death ligand 1 (PD-L1), has changed practices in oncology, becoming a new standard of care in first or subsequent lines for several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd67ebb54cfde1517bd3e0828c1cf000
https://doi.org/10.1016/j.ejca.2021.09.013
https://doi.org/10.1016/j.ejca.2021.09.013
Autor:
Mathieu Larroquette, Félix Lefort, Luc Heraudet, Jean-Christophe Bernhard, Alain Ravaud, Charlotte Domblides, Marine Gross-Goupil
Publikováno v:
Cancers. 14(24)
Clear cell renal cell carcinoma (RCC) oncogenesis is mainly driven by VHL gene inactivation, leading to overexpression of vascular endothelial growth factor (VEGF). The use of tyrosine-kinase inhibitors (TKIs) directed against VEGF and its receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e644fb67d1abd7f4537327bff005b38b
https://pubmed.ncbi.nlm.nih.gov/36551715
https://pubmed.ncbi.nlm.nih.gov/36551715
Autor:
Lucie Meynard, Derek Dinart, Blandine Delaunay, Aude Fléchon, Carolina Saldana, Félix Lefort, Gwenaëlle Gravis, Antoine Thiery-Vuillemin, Mathilde Cancel, Elodie Coquan, Sylvain Ladoire, Denis Maillet, Frédéric Rolland, Elouen Boughalem, Sophie Martin, Mathieu Laramas, Laurence Crouzet, Baptiste Abbar, Sabrina Falkowski, Damien Pouessel, Guilhem Roubaud
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2022, 175, pp.43-53. ⟨10.1016/j.ejca.2022.08.014⟩
European Journal of Cancer, 2022, 175, pp.43-53. ⟨10.1016/j.ejca.2022.08.014⟩
International audience; BACKGROUND: Recent studies suggest improvements in response to salvage chemotherapy (CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was to assess the efficacy of chemotherapy re-challen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::487550534cd14c3ce43c37475956af00
https://pubmed.ncbi.nlm.nih.gov/36088671
https://pubmed.ncbi.nlm.nih.gov/36088671
Autor:
Félix Lefort, Baptiste Sionneau, Charlotte Domblides, Quentin Durrechou, Amandine Quivy, Marine Gross-Goupil, Alain Ravaud, Amaury Daste
Publikováno v:
Cancer Management and Research. 12:9139-9158
Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f776bd078416aadbbbdae69d935e6074
https://doi.org/10.2147/cmar.s218756
https://doi.org/10.2147/cmar.s218756
Autor:
Luc Heraudet, Alain Ravaud, Amaury Daste, Félix Lefort, Jean-Christophe Bernhard, Charlotte Domblides, Marine Gross-Goupil
Publikováno v:
Expert Opinion on Drug Safety. 19:799-806
The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer.In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd7e982ef27840d8268faf841f15d61
https://doi.org/10.1080/14740338.2020.1774551
https://doi.org/10.1080/14740338.2020.1774551
Autor:
Estelle Granet-Vaissiere, Félix Lefort, Charlotte Domblides, Mathieu Larroquette, Alain Ravaud, Jean-Christophe Bernhard, Marine Gross-Goupil
Publikováno v:
Cancers. 15:1048
Over the past decade, major advances have been made in the treatment of advanced and metastatic renal cell carcinomas, specifically clear cell carcinomas. For many years the optimal approach was sequential; thus, monotherapies [principally tyrosine k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce5fb84091864586a74c62b1a1605963
https://doi.org/10.3390/cancers15041048
https://doi.org/10.3390/cancers15041048
Autor:
Félix Lefort, Charlotte Domblides, Marine Gross-Goupil, Jean-Christophe Bernhard, Alain Ravaud, Florent Peyraud, Mathieu Larroquette
Publikováno v:
Cancer treatment reviews. 97
While many patients with non-metastatic renal cell carcinoma (RCC) can be cured with surgery alone, upward of 40% of patients recur in a short delay, raising the question of additional perioperative treatments. To address this clinical need, multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d756c651cdfa3c61d2ef6dc90aaf456
https://pubmed.ncbi.nlm.nih.gov/33906023
https://pubmed.ncbi.nlm.nih.gov/33906023